This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Seres Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.972. Seres Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-24), Seres Therapeutics's share price is $0.76. Seres Therapeutics's Median PS Value is $0.00. Therefore, Seres Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Seres Therapeutics's Median PS Value or its related term are showing as below:
MCRB's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.665 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Seres Therapeutics Median PS Value Historical Data
The historical data trend for Seres Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seres Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seres Therapeutics Price-to-Median-PS-Value Distribution
For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Seres Therapeutics's Price-to-Median-PS-Value falls into.
Seres Therapeutics Median PS Value Calculation
Seres Therapeutics's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Seres Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.972.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seres Therapeutics (NAS:MCRB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Seres Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.76
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seres Therapeutics Median PS Value Related Terms
Thank you for viewing the detailed overview of Seres Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Seres Therapeutics (Seres Therapeutics) Business Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCRB has been successfully added to your 